Expertise in
10
conditions

Dr. Philip J. Mease

Rheumatology
601 Broadway, 
Seattle, WA 
Accepting New Patients
Offers Telehealth
44 Years of Experience
Expertise in
10
conditions
601 Broadway, 
Seattle, WA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Philip Mease is a Rheumatologist in Seattle, Washington. Dr. Mease has been practicing medicine for over 44 years is highly rated in 10 conditions, according to our data. His top areas of expertise are Psoriatic Arthritis, Arthritis, Psoriasis, and Axial Spondyloarthritis (AxSpA). Dr. Mease is currently accepting new patients.

His clinical research consists of co-authoring 524 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Rheumatology
Licenses
Internal Medicine in WA
Hospital Affiliations
Swedish Medical Center
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Group Health Cooperative
  • HMO
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Lifewise

Accepted plan types not found. Please verify directly with the provider.

PacificSource
  • PPO
Premera
  • EPO
  • PPO
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
Regence
  • EPO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
View 7 Less Insurance Carriers -

Locations

601 Broadway, Seattle, WA 98122

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Phase 3, Double-Blind, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
A Phase 3, Double-Blind, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
Enrollment Status: Terminated
Publish Date: May 16, 2023
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients With Systemic Lupus Erythematosus
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients With Systemic Lupus Erythematosus
Enrollment Status: Terminated
Publish Date: January 30, 2023
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
CLassification of Axial SpondyloarthritiS Inception Cohort
CLassification of Axial SpondyloarthritiS Inception Cohort
Enrollment Status: Completed
Publish Date: December 08, 2022
Treatments Against RA and Effect on FDG-PET/CT (The TARGET Trial)
Treatments Against RA and Effect on FDG-PET/CT (The TARGET Trial)
Enrollment Status: Completed
Publish Date: October 26, 2022
Intervention Type: Drug
Study Drugs: Methotrexate, Sulfasalazine, Hydroxychloroquine, Etanercept, Adalimumab
Study Phase: Phase 4
A Multicenter, Long-Term Extension Study of 104 Weeks, Including a Double-Blind, Placebo-Controlled 40-Week Randomized Withdrawal-Retreatment Period, to Evaluate the Maintenance of Treatment Effect of Ixekizumab (LY2439821) in Patients With Axial Spondyloarthritis
A Multicenter, Long-Term Extension Study of 104 Weeks, Including a Double-Blind, Placebo-Controlled 40-Week Randomized Withdrawal-Retreatment Period, to Evaluate the Maintenance of Treatment Effect of Ixekizumab (LY2439821) in Patients With Axial Spondyloarthritis
Enrollment Status: Completed
Publish Date: June 13, 2022
Intervention Type: Drug
Study Phase: Phase 3
A Multicenter, Randomized, Double-Blind, Placebo- Controlled 16-Week Study Followed by Long-Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in TNFi-Experienced Patients With Radiographic Axial Spondyloarthritis
A Multicenter, Randomized, Double-Blind, Placebo- Controlled 16-Week Study Followed by Long-Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in TNFi-Experienced Patients With Radiographic Axial Spondyloarthritis
Enrollment Status: Completed
Publish Date: June 17, 2020
Intervention Type: Drug
Study Phase: Phase 3
A 52-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD Naive Patients With Nonradiographic Axial Spondyloarthritis
A 52-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD Naive Patients With Nonradiographic Axial Spondyloarthritis
Enrollment Status: Completed
Publish Date: March 13, 2020
Intervention Type: Drug
Study Phase: Phase 3
View 6 Less Clinical Trials

524 Total Publications

GRAPPA 2024 Annual Meeting: An Update on Major Project Milestones.
GRAPPA 2024 Annual Meeting: An Update on Major Project Milestones.
Journal: The Journal of rheumatology
Published: October 01, 2025
Similar Doctors
Expertise in
25
conditions
Dr. Jeffrey S. Carlin
Rheumatology
Expertise in
25
conditions
Dr. Jeffrey S. Carlin
Rheumatology

The Association Of University Physicians

1959 Ne Pacific St, 
Seattle, WA 
 (3.0 miles away)
206-598-4333
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Jeffrey Carlin is a Rheumatologist in Seattle, Washington. Dr. Carlin is highly rated in 25 conditions, according to our data. His top areas of expertise are Systemic Sclerosis (SSc), Rheumatoid Arthritis (RA), Scleroma, and Scleroderma. Dr. Carlin is currently accepting new patients.

Expertise in
7
conditions
Dr. Alison M. Bays
Rheumatology
Expertise in
7
conditions
Dr. Alison M. Bays
Rheumatology

The Association Of University Physicians

325 9th Ave, 
Seattle, WA 
 (0.3 miles away)
206-731-3000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Alison Bays is a Rheumatologist in Seattle, Washington. Dr. Bays is highly rated in 7 conditions, according to our data. Her top areas of expertise are Giant Cell Arteritis (GCA), Temporal Arteritis, Juvenile Temporal Arteritis, and Lupus Nephritis. Dr. Bays is currently accepting new patients.

Expertise in
7
conditions
Dr. Jeffrey L. Mathews
Rheumatology
Expertise in
7
conditions
Dr. Jeffrey L. Mathews
Rheumatology

Overlake Arthritis And Osteoporosis Center PLLC

2100 116th Ave Ne, 
Bellevue, WA 
 (6.5 miles away)
425-453-0766
Languages Spoken:
English, Swedish
See accepted insurances
Accepting New Patients

Jeffrey Mathews is a Rheumatologist in Bellevue, Washington. Dr. Mathews is highly rated in 7 conditions, according to our data. His top areas of expertise are Ankylosing Spondylitis, Rheumatoid Lung Disease, Rheumatoid Pneumoconiosis, and Axial Spondyloarthritis (AxSpA). Dr. Mathews is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Mease's expertise for a condition
ConditionClose
View All 8 Elite Conditions
    View All 15 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile